1. Scrip
  2. >>Business
  3. >>Financing

AMR Action Fund Will Start Screening Antibiotic Candidates Early Next Year

 
• By Joseph Haas

The industry-backed investment fund to combat antimicrobial resistance hopes to be operational by end of year and begin assessing programs to invest in during the first quarter of 2021.

Virus
The ACR Action Fund is meant to be a temporary solution for novel antibiotics

The AMR Action Fund hopes to be operational by the end of 2020 and begin reviewing novel antibiotic candidates to invest in during the first quarter of 2021, interim general manager Martin Bott told the virtual BIO Investor Forum on 13 October. Its focus will be on mid-stage antibiotic candidates, leaving earlier investment support to other groups.

The fund has been in planning since mid-2019, arising from discussions at an international conference, and was unveiled in July....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By Vibha Ravi

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers

Finance Watch: Two New Venture Capital Funds Provide $600m For Biopharma

 
• By Mandy Jackson

Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.